Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001610618-17-000026
Filing Date
2017-04-28
Accepted
2017-04-28 16:06:07
Documents
4
Period of Report
2017-06-22
Effectiveness Date
2017-04-28

Document Format Files

Seq Description Document Type Size
1 2017 PROXY STATEMENT cdtxdef14a2017-04x28.htm DEF 14A 488407
2 cdtxlogo.jpg GRAPHIC 46741
3 proxycard001.jpg GRAPHIC 141560
4 proxycard002.jpg GRAPHIC 123066
  Complete submission text file 0001610618-17-000026.txt   913463
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36912 | Film No.: 17795436
SIC: 2836 Biological Products, (No Diagnostic Substances)